Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.67 -1.07 (-2.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

EXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals ↗

July 02, 2025

EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential ↗

June 30, 2025

EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.

Via Chartmill

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

June 28, 2025

Via The Motley Fool

Topics Intellectual Property

EXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup ↗

June 28, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support...

Via Chartmill

This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday ↗

June 24, 2025

Via Benzinga

Analyst Expectations For Exelixis's Future ↗

June 05, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing ↗

June 24, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.

Via Chartmill

CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug ↗

June 23, 2025

CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.

Via Investor's Business Daily

Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday ↗

June 23, 2025

Via Benzinga

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars ↗

June 23, 2025

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.

Via Benzinga

AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday ↗

June 23, 2025

Via Benzinga

Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug ↗

June 23, 2025

Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.

Via Investor's Business Daily

What 9 Analyst Ratings Have To Say About Exelixis ↗

June 23, 2025

Via Benzinga

These stocks are moving in today's pre-market session ↗

June 23, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 23, 2025

Via Benzinga

Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket ↗

June 23, 2025

Via Benzinga

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

June 22, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

June 20, 2025

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors ↗

June 17, 2025

EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation ↗

June 13, 2025

EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.

Via Chartmill

DoorDash To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗

June 12, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Undervalued Biotech Stocks ↗

June 10, 2025

EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, growth, and financial health, making it a compelling pick for value investors.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup ↗

June 06, 2025

EXELIXIS INC (NASDAQ:EXEL) combines strong earnings momentum with a high technical rating, making it a standout for growth investors. The stock's breakout setup suggests potential upside.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential ↗

June 03, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities.

Via Chartmill

2 Top Stocks to Buy With Less Than $100 ↗

May 30, 2025

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors ↗

May 26, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.

Via Chartmill

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 22, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 22, 2025

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation ↗

May 22, 2025

EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – An Undervalued Biotech Stock with Strong Fundamentals ↗

May 20, 2025

EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Exelixis, Inc. - Common Stock (NQ:EXEL)

All News about Exelixis, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today